Platelet pathology and antiplatelet strategies

References
1 Scharf RE. Platelet pathology and vascular medicine. Hämostaseologie 2015; 35: 9.
2 Scharf RE. Von Willebrand factor, hemostasis and inflammation. Hämostaseologie 2015; 35: 209-210.
3 Ruggeri ZM, Mendolicchio GL. Interaction of von Willebrand factor with platelets and the vessel wall. Hämostaseologie 2015; 35: 211-224.
4 Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007; 100: 1673-1685.
5 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-250.
6 Vögtle T, Cherpokova D, Bender M, Nieswandt B. Targeting platelet receptors in thrombotic and thrombo-inflammatory disorders. Hämostaseologie 2015; 35: 235-243.
7 Assinger A. Platelets and infection – an emerging role of platelets in viral infection. Front Immunol 2014; 5: 649.
8 Duchene J, von Hundelshausen P. Platelet-derived chemokines in atherosclerosis. Hämostaseologie 2015; 35: 137-141.
9 Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131-2137.
10 Gupta GP, Massague J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest 2004; 114: 1691-1693.
11 Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost 2014; 40: 277-283.
12 Mammadova-Bach E, Mangin P, Lanza F, Gachet C. Platelets in cancer. From basic research to therapeutic implications. Hämostaseologie 2015; 35: 325-336.
13 Semple JW, Italiano Jr, JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11: 264-274.
14 Scharf RE, Bode C. 59^th Annual Congress of the Gesellschaft für Thrombose- und Hämostaseforschung e.V. Message from the Congress Presidents. Hämostaseologie 2015; 35: 3-5.
15 Scharf RE. Coagulation disorders. Recent lessens from clinical conditions. Hämostaseologie 2015; 35: 301-302.
16 Mauler M, Bode C, Duerschmied D. Platelet serotonin modulates immune functions. Hämostaseologie 2016; 36: 11-16.
17 Scharf RE. Management of bleeding in patients using antithrombotic agents. Prediction, prevention, protection and problem-oriented intervention. Hämostaseologie 2009; 29: 388-398.
18 Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38: 865-883.
19 Labberton L, Kenne E, Renne T. New agents for thromboprotection. A role for factor XII and XIIa inhibition. Hämostaseologie 2015; 35: 338-350.
20 Hohmann JD, Wang X, Krajewski S. et al. Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding?. Blood 2013; 121: 3067-3075.
21 Hohmann JD, Peter K. Activated-platelet targeting of CD39 as a potential way forward. Hämostaseologie 2016; 36: 17-25.
22 Lüscher TF, Steffel J. Individualized antithrombotic therapy. Hämostaseologie 2016; 36: 26-32.
23 Schrör K. Why we should not skip aspirin in cardiovascular prevention. Hämostaseologie 2016; 36: 33-43.
24 Yasu T, Oshima S, Imanishi M. et al. Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris. Am J Cardiol 1993; 71: 1164-1168.
25 Moser M. Peri- and postinterventional antithrombotic therapy in TAVI. Do we need antiplatelet therapy. Hämostaseologie 2016; 36: 44-45.
26 Rodes-Cabau J, Dauerman HL, Cohen MG. et al. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J Am Coll Cardiol 2013; 62: 2349-2359.
27 Polzin A, Schleicher M, Seidel H. et al. High on-treatment platelet reactivity in transcatheter aortic valve implantation patients. Eur J Pharmacol 2015; 751: 24-27.
28 Zotz RB, Finger C, Scharf RE, Unsöld R. Associations between thrombophilic risk factors and determinants of atherosclerosis and inflammation in patients with non-arteritic anterior ischaemic optic neuropathy. Hämostaseologie 2016; 36: 46-54.